SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001654954-18-013922
Filing Date
2018-12-13
Accepted
2018-12-13 16:39:18
Documents
3
Period of Report
2018-12-07
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT azrx8k_dec72018.htm 8-K 35991
2 ASSET SALE AND PURCHASE AGREEMENT, DATED DECEMBER 7, 2018, BY AND BETWEEN PROTEA ex10-1.htm EX-10.1 138666
3 PRESS RELEASE ex99-1.htm EX-99.1 9778
  Complete submission text file 0001654954-18-013922.txt   185639
Mailing Address 760 PARKSIDE AVENUE SUITE 304 BROOKLYN NY 11226
Business Address 760 PARKSIDE AVENUE SUITE 304 BROOKLYN NY 11226 646-699-7855
AzurRx BioPharma, Inc. (Filer) CIK: 0001604191 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE
Type: 8-K | Act: 34 | File No.: 001-37853 | Film No.: 181233658
SIC: 2834 Pharmaceutical Preparations
Assistant Director 1